Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
LAVA Therapeutics N.V. - Ordinary Shares
(NQ:
LVTX
)
1.330
-0.020 (-1.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about LAVA Therapeutics N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
February 28, 2025
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.
Via
Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
February 27, 2025
Via
Benzinga
On Wednesday, there are stocks with unusual volume. Let's take a look.
February 26, 2025
These stocks have an unusual volume in today's session
Via
Chartmill
What's going on in today's session
February 25, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
What 5 Analyst Ratings Have To Say About LAVA Therapeutics
August 23, 2023
Via
Benzinga
Which stocks are experiencing notable movement on Tuesday?
February 25, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session.
February 25, 2025
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
Via
Chartmill
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
August 20, 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
June 10, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 21, 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 20, 2024
LVTX stock results show that LAVA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
March 05, 2024
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via
AB Newswire
Topics
Retirement
Exposures
Pension
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
January 26, 2024
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.
Via
Benzinga
Topics
Government
Exposures
Political
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 26, 2024
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!
Via
InvestorPlace
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 25, 2024
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Via
Benzinga
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
January 25, 2024
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Dow Surges Over 100 Points; US GDP Growth Tops Estimates
January 25, 2024
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.33% to 37,932.33 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
January 25, 2024
LAVA Therapeutics collaborates with Merck on a clinical trial for anti-PD-1 therapy Keytruda in metastatic castration-resistant prostate cancer.
Via
Benzinga
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
January 25, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 16, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 22, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.